A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Asahina, Hajime; Yamazaki, K; Kinoshita, Ichiro; Sukoh, Noriaki; Harada, M.; Yokouchi, Hiroshi; Ishida, Takashi; Ogura, Shinji; Kojima, Taro; Okamoto, Yasushi; Fujita, Yasuko; Dosaka‐Akita, Hirotoshi; Isobe, Hiroshi; Nishimura, Masaharu

doi:10.1038/sj.bjc.6603393

Public

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Published in British Journal of Cancer • Oct 1, 2006

Authors:

Hajime Asahina

K Yamazaki

Ichiro Kinoshita

Abstract

Retrospective analysis has shown that activating mutations in exons 18-21 of the epidermal growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for advanced non-small cell lun...

Subject

Gefitinib

Epidermal growth factor receptor

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!